Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation

Welcome to Not So Different, a podcast from The Center for Biosimilars®. I’m your host, Assistant Editor Skylar Jeremias.

A recently published opinion piece from 2 executives of Sandoz and Boehringer Ingelheim argued that misinformation is weakening patient and physician trust in biosimilars, preventing access to these lower-cost biologics, and slowing their uptake in the United States. The authors also called for changes in standard biosimilar terminology that they say misleads the public about the safety and use of these products.

We sat down with an author of the opinion piece, Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmaceuticals and co-chair of the Biosimilars Forum education committee, to discuss what more needs to be done to combat biosimilar misinformation and how patients and physicians can help the cause.

To learn more about the opinion piece McCabe co-authored, click here.

To learn more about Boehringer Ingelheim, visit boehringer-ingelheim.com.